Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Esophageal cancer
Stage/Subtype:  stage III esophageal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 32 for your search:
Start Over
Radiation Therapy, Paclitaxel, and Carboplatin with or without Trastuzumab in Treating Patients with Esophageal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: RTOG 1010, NCI-2011-02601, CDR0000683717, NCT01196390
Proton Beam Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Esophageal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1036, NCI-2012-00078, NCT01512589
Radiation Therapy with Docetaxel and Fluorouracil in Treating Patients with Esophageal Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0847, NCI-2011-02030, NCT01102088
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Combination Chemotherapy Followed by Radiation Therapy, Carboplatin, and Everolimus in Treating Patients with Esophageal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001CUS159T, NCI-2012-00166, WCI1871-10, NCT01490749
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLJM716X2103, NCI-2013-01355, NCT01822613
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: FER-GI-029, NCI-2013-00603, IRB#10-022, NCT01212822
Panitumumab, Combination Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Advanced Esophageal or Gastroesophageal Junction Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 221-09, NCI-2010-02056, NCT01307956
Combination Chemotherapy in Treating Patients with Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309035, NCI-2013-01783, NCT01928290
MatriStem Surgical Matrix PSM in Reducing Complications in Patients with Stomach or Esophageal Cancer Undergoing Surgery
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 13-178, NCI-2013-02006, NCT01970306
Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU021212I, NCI-2014-01962, NCT02234180
Afatinib and Paclitaxel in Treating Patients with HER2-Positive Recurrent Advanced Gastric, Gastroesophageal Junction, or Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAM5905, NCI-2015-00758, 1200.203, NCI-2014-02350, NCT02274012
Personalized Therapy Using Genetic Markers in Treating Patients with Esophagogastric Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412051, NCI-2014-02550, NCT02296671
Molecular Phenotyping in Predicting Response in Patients with Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 9314, NCI-2015-00034, NCT02392377
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Vaccine Therapy in Treating Patients with Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor 2 Positive Cancers
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00034612, NCI-2013-00525, NCT01526473
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B2151002, NCI-2013-01814, 2013-001390-24, NCT01920061
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Start Over